Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Protocol No

HJKC3-0003

Staff Member

Ehab Atallah

Phase

Summary

The purpose of this study is to determine if adding asciminib to imatinib prior to a second attempt at stopping imatinib will lead to prolonged treatment free remission.

Objective

Treatment Free Remission After Asciminib plus Imatinib in CP-CML

Study Sites

Moorland Reserve Health Center Memorial Sloan Kettering Cancer Center - Monmouth Memorial Sloan Kettering Cancer Center University of Utah Huntsman Cancer Institute Lawrence And Idell Weisberg Cancer Treatment Center Karmanos Cancer Institute Froedtert Hospital Memorial Sloan Kettering Cancer Center - Bergen

Status

OPEN TO ACCRUAL